Back to Directory
Last Updated: 08/05/2026

Trio Medicines

London
Founded 2005
GPCR-targeted small molecule drugs for rare and inflammatory disease

Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need.

Its pipeline includes gastrin/CCK2 receptor antagonists for gastric neuroendocrine tumours, a selective β2-adrenoceptor antagonist, and a formyl peptide receptor agonist with anti-inflammatory potential.

The company operates within the facilities of its parent company, Hammersmith Medicines Research, a London-based clinical CRO.

BiotechDrug DiscoveryOncologyImmunology
Small Molecule DrugsRare DiseasesCardiovascularRespiratory Disease

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of